MedTrace Logo

Gene Modulation of NLRP3, IL-1β and TNF-α in Peripheral Blood of Patients With Exogenous Obesity Treated With Berberine

NCT06703086 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2024-11-25

No results posted yet for this study

Summary

The patients will be invited to participate in a research study aimed at determining the Gene Modulation of NLRP3, IL-1β and TNFα in peripheral blood of patients with exogenous obesity treated with berberine.

Conditions

Interventions

DIETARY_SUPPLEMENT

Berberine Hydrochloride group

The patient will be given a nutritional plan, moderate aerobic exercise with a goal of 10,000 steps or 150 min per week; and the phytopharmaceutical Berberine will be taken 3 tablets ( 500 mg) every 8 hours for 3 months.

BEHAVIORAL

nutritional plan

nutritional plan according to your caloric requirements for lifestyle change and you will be scheduled biweekly for 3 months

BEHAVIORAL

controlled moderate aerobic exercise

controlled moderate aerobic exercise that will consist of a goal of 10,000 steps or 150 minutes per week.

Sponsors & Collaborators

  • National Polytechnic Institute, Mexico

    lead OTHER

Principal Investigators

  • Nadia-Mabel PV PhD Nadia Mabel Pérez Vielma, PhD · 044-5520583053

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-01-05
Primary Completion
2019-08-15
Completion
2020-02-15

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06703086 on ClinicalTrials.gov